Pharmacogenetics of intravenous and oral busulfan in hematopoietic cell transplant recipients

Journal of Clinical Pharmacology

Volumn 51, Issue 10, 2011, Pages 1429-1438

  Abbasi, Nissa ^a   Vadnais, Barbara ^d   Knutson, Jennifer A ^a   Blough, David K ^a,c   Kelly, Edward J ^a   O'Donnell, Paul V ^b,c   Deeg, H Joachim ^b,c   Pawlikowski, Matthew A ^e   Ho, Rodney J Y ^a,c   McCune, Jeannine S ^a,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Medicine   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^e SEATTLE CANCER CARE ALLIANCE   (United States)

Author keywords

busulfan; glutathione S transferase; hematopoietic cell transplant; pharmacogenetic; therapeutic drug monitoring

Indexed keywords

BUSULFAN; GLUTATHIONE TRANSFERASE A1; GLUTATHIONE TRANSFERASE M1;

ADULT; ARTICLE; DRUG CLEARANCE; FEMALE; GENE; GENETIC VARIABILITY; GENOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; RETROSPECTIVE STUDY;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; BUSULFAN; FEMALE; GENE EXPRESSION REGULATION; GENOTYPE; GLUTATHIONE TRANSFERASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 80053227750     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010382915     Document Type: Article

References (43)

1. Deeg HJ, Maris MB, Scott BL, Warren EH. Optimization of allogeneic transplant conditioning: not the time for dogma. Leukemia. 2006 ; 20 (10). 1701-1705 (Pubitemid 44590959)
2. McCune JS, Gibbs JP, Slattery JT. Plasma concentration monitoring of busulfan: does it improve clinical outcome?. Clin Pharmacokinet. 2000 ; 39 (2). 155-165
3. Field T, Perkins J, Alsina M, et al. Busulfan area-under-the-curve finding study within a busulfan/fludarabine (BuFlu) conditioning regimen before allogeneic hematopoietic cell transplantation (HCT). Blood. 2006 ; 108 ( 11 ):
4. Undevia SD, Gomez-Abuin G, Ratain MJ. Pharmacokinetic variability of anticancer agents. Nat Rev Cancer. 2005 ; 5 (6). 447-458 (Pubitemid 40791487)
5. Deeg HJ, Storer BE, Boeckh M, et al. Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. Biol Blood Marrow Transplant. 2006 ; 12 (5). 573-584 (Pubitemid 43956362)
6. Radich JP, Gooley T, Bensinger W, et al. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood. 2003 ; 102 (1). 31-35 (Pubitemid 36759632)
7. Nadkarni MV, Trams EG, Smith PK. Preliminary studies on the distribution and fate of TEM, TEPA, and myeleran in the human. Cancer Res. 1959 ; 19: 713-718
8. Vodopick H, Hamilton HE, Jackson HL, Peng CT, Sheets RF. Metabolic fate of tritiated busulfan in man. J Lab Clin Med. 1969 ; 73 (2). 266-276
9. Ehrsson H, Hassan M. Binding of busulfan to plasma proteins and blood cells. J Pharm Pharmacol. 1984 ; 36 (10). 694-696 (Pubitemid 14000399)
10. Hassan M, Oberg G, Ehrsson H, et al. Pharmacokinetic and metabolic studies of high-dose busulphan in adults. Eur J Clin Pharmacol. 1989 ; 36 (5). 525-530 (Pubitemid 19135219)
11. Ehrsson H, Hassan M, Ehrnebo M, Beran M. Busulfan kinetics. Clin Pharmacol Ther. 1983 ; 34: 86-89 (Pubitemid 13073308)
12. Busulfex (busulfan) [package insert]. Tokyo, Japan: Otsuka America Pharmaceutical; 2008. http://www.ivbusulfex.com/Otsuka-IVBusulfex-v2AA.pdf. Accessed May 30, 2008.
13. Gibbs JP, Murray G, Risler L, Chien JY, Dev R, Slattery JT. Age-dependent tetrahydrothiophenium ion formation in young children and adults receiving high-dose busulfan. Cancer Res. 1997 ; 57 (24). 5509-5516 (Pubitemid 28006757)
14. Hassan M, Ljungman P, Bolme P, et al. Busulfan bioavailability. Blood. 1994 ; 84 (7). 2144-2150 (Pubitemid 24296370)
15. Hassan M, Ehrsson H, Ljungman P. Aspects concerning busulfan pharmacokinetics and bioavailability. Leuk Lymphoma. 1996 ; 22 (5-6). 395-407 (Pubitemid 26341005)
16. Hassan M, Ehrsson H. Metabolism of 14C-busulfan in isolated perfused rat liver. Eur J Drug Metab Pharmacokinet. 1987 ; 12 (1). 71-76 (Pubitemid 17120684)
17. Gibbs JP, Czerwinski M, Slattery JT. Busulfan-glutathione conjugation catalyzed by human liver cytosolic glutathione S-transferases. Cancer Res. 1996 ; 56 (16). 3678-3681 (Pubitemid 26272012)
18. Czerwinski M, Gibbs JP, Slattery JT. Busulfan conjugation by glutathione S-transferases alpha, mu, and pi. Drug Metab Dispos. 1996 ; 24 (9). 1015-1019 (Pubitemid 26314555)
19. Bredschneider M, Klein K, Murdter TE, et al. Genetic polymorphisms of glutathione S-transferase A1, the major glutathione S-transferase in human liver: consequences for enzyme expression and busulfan conjugation. Clin Pharmacol Ther. 2002 ; 71 (6). 479-487 (Pubitemid 34701355)
20. Coles BF, Morel F, Rauch C, et al. Effect of polymorphism in the human glutathione S-transferase A1 promoter on hepatic GSTA1 and GSTA2 expression. Pharmacogenetics. 2001 ; 11 (8). 663-669 (Pubitemid 33078235)
21. Bolt HM, Thier R. Relevance of the deletion polymorphisms of the glutathione S-transferases GSTT1 and GSTM1 in pharmacology and toxicology. Curr Drug Metab. 2006 ; 7 (6). 613-628 (Pubitemid 44226589)
22. Srivastava A, Poonkuzhali B, Shaji RV, et al. Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood. 2004 ; 104 (5). 1574-1577 (Pubitemid 39166540)
23. Pai MP, Paloucek FP. The origin of the "ideal" body weight equations. Ann Pharmacother. 2000 ; 34 (9). 1066-1069 (Pubitemid 30660784)
24. Slattery JT, Risler LJ. Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation. Ther Drug Monit. 1998 ; 20 (5). 543-549 (Pubitemid 28463447)
25. Guidelines for Collection and Analysis of Pharmacokinetic Data. 4 th ed.Philadelphia: Lippincott Williams & Wilkins; 2006. Jusko WJ, ed. Philadelphia: Lippincott Williams & Wilkins ; 2006 :
26. McCune JS, Holmberg LA. Busulfan in hematopoietic stem cell transplant setting. Expert Opin Drug Metab Toxicol. 2009 ; 5 (8). 957-969
27. Madden T, de Lima M, Thapar N, et al. Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule. Biol Blood Marrow Transplant. 2007 ; 13 (1). 56-64 (Pubitemid 46044090)
28. Murry DJ, Crom WR, Reddick WE, Bhargava R, Evans WE. Liver volume as a determinant of drug clearance in children and adolescents. Drug Metab Dispos. 1995 ; 23 (10). 1110-1116
29. Kusama M, Kubota T, Matsukura Y, et al. Influence of glutathione S-transferase A1 polymorphism on the pharmacokinetics of busulfan. Clin Chim Acta. 2006 ; 368 (1-2). 93-98 (Pubitemid 43776023)
30. Johnson L, Orchard PJ, Baker KS, et al. Glutathione S-transferase A1 genetic variants reduce busulfan clearance in children undergoing hematopoietic cell transplantation. J Clin Pharmacol. 2008 ; 48 (9). 1052-1062
31. Zwaveling J, Press RR, Bredius RG, et al. Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients. Ther Drug Monit. 2008 ; 30 (4). 504-510
32. Ansari M, Lauzon-Joset JF, Vachon MF, et al. Influence of GST gene polymorphisms on busulfan pharmacokinetics in children. Bone Marrow Transplant. 2010 ; 45 (2). 261-267
33. Hassan M, Oberg G, Bjorkholm M, Wallin I, Lindgren M. Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemother Pharmacol. 1993 ; 33 (3). 181-186 (Pubitemid 23361064)
34. Sandstrom M, Karlsson MO, Ljungman P, et al. Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients. Bone Marrow Transplant. 2001 ; 28 (7). 657-664 (Pubitemid 33014599)
35. Kim I, Keam B, Lee KH, et al. Glutathione S-transferase A1 polymorphisms and acute graft-vs.-host disease in HLA-matched sibling allogeneic hematopoietic stem cell transplantation. Clin Transplant. 2007 ; 21 (2). 207-213 (Pubitemid 46505728)
36. Slattery JT, Clift RA, Buckner CD, et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood. 1997 ; 89 (8). 3055-3060 (Pubitemid 27172594)
37. Terakura S, Murata M, Nishida T, et al. Increased risk for treatment-related mortality after bone marrow transplantation in GSTM1-positive recipients. Bone Marrow Transplant. 2006 ; 37 (4). 381-386 (Pubitemid 43250472)
38. Kletzel M, Jacobsohn D, Duerst R. Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006 ; 12 (4). 472-479 (Pubitemid 43380964)
39. Ott MG, Schmidt M, Schwarzwaelder K, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. 2006 ; 12 (4). 401-409
40. Aiuti A, Slavin S, Aker M, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 2002 ; 296 (5577). 2410-2413 (Pubitemid 34734219)
41. Kahl CA, Tarantal AF, Lee CI, et al. Effects of busulfan dose escalation on engraftment of infant rhesus monkey hematopoietic stem cells after gene marking by a lentiviral vector. Exp Hematol. 2006 ; 34 (3). 369-381
42. Salinger DH, Vicini P, Blough DK, O'Donnell PV, Pawlikowski MA, McCune JS. Development of a population pharmacokinetics-based sampling schedule to target daily intravenous busulfan for outpatient clinic administration [published online ahead of print Janaury 14, 2010]. J Clin Pharmacol. :
43. Bleyzac N, Souillet G, Magron P, et al. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant. 2001 ; 28 (8). 743-751 (Pubitemid 33089217)